保健品
膳食补充剂
医学
不利影响
食品药品监督管理局
药品
食品补充剂
健康福利
生物技术
环境卫生
药理学
传统医学
食品科学
生物
病理
作者
Martin J. J. Ronis,Kim Brint Pedersen,James Watt
出处
期刊:Annual Review of Pharmacology and Toxicology
[Annual Reviews]
日期:2018-01-06
卷期号:58 (1): 583-601
被引量:242
标识
DOI:10.1146/annurev-pharmtox-010617-052844
摘要
Over 70% of Americans take some form of dietary supplement every day, and the supplement industry is currently big business, with a gross of over $28 billion. However, unlike either foods or drugs, supplements do not need to be registered or approved by the US Food and Drug Administration (FDA) prior to production or sales. Under the Dietary Supplement Health and Education Act of 1994, the FDA is restricted to adverse report monitoring postmarketing. Despite widespread consumption, there is limited evidence of health benefits related to nutraceutical or supplement use in well-nourished adults. In contrast, a small number of these products have the potential to produce significant toxicity. In addition, patients often do not disclose supplement use to their physicians. Therefore, the risk of adverse drug-supplement interactions is significant. An overview of the major supplement and nutraceutical classes is presented here, together with known toxic effects and the potential for drug interactions.
科研通智能强力驱动
Strongly Powered by AbleSci AI